Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS in Asymptomatic Antibody-Mediated TTP
NCT02854059Phase 2Terminated
- Sponsor
- Hansa Biopharma
- Start
- Sep 2016
- Primary completion
- Jan 2017
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of imlifidase in thrombotic thrombocytopenic purpura (TTP), sponsored by Hansa Biopharma. Started Sep 2016; status: terminated.
02
Drugs
imlifidase
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on NCT02854059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02854059.